In Jan 2017, the first patient was dosed in a phase III study (FORWARD I) of its lead candidate mirvetuximab soravtansine, for the treatment of platinum-resistant ovarian cancer. Guidance Updated: The company issued its financial guidance for 2017. Revenues are expected in the range of $70 million and $75 million, which includes $28 million of expected upfront and milestone fees from partners. Operating expenses are projected in the range of $175 million and $180 million for 2017. Share Price Impact: In-active in pre-market trading. Check back later for our full write up on IMGN earnings report later!